| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/03/2008 | WO2008079030A1 Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| 07/03/2008 | WO2008078730A1 Preparation for transnasal application |
| 07/03/2008 | WO2008078588A1 Pharmaceutical agent and method for treatment or prevention of articular cartilage deformation |
| 07/03/2008 | WO2008078387A1 Fermented milk for improving and/or treating skin and method for producing the same |
| 07/03/2008 | WO2008078325A2 A method of treating schizophrenia |
| 07/03/2008 | WO2008078189A2 Factor vii and viia compositions |
| 07/03/2008 | WO2008078179A1 Trkb agonists for treating autoimmune disorders |
| 07/03/2008 | WO2008078177A2 Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence |
| 07/03/2008 | WO2008078167A2 Consensus peptide |
| 07/03/2008 | WO2008077993A1 Novel peptides |
| 07/03/2008 | WO2008077977A1 Therapeutic agents for treatment of malaria |
| 07/03/2008 | WO2008077956A2 Oligonucleotide-, protein and/or peptide-polymer conjugates |
| 07/03/2008 | WO2008077616A1 Modified coagulation factors with prolonged in vivo half-life |
| 07/03/2008 | WO2008077529A1 Synergistic therapeutic use of prothrombin complex concentrates with fviii concentrates |
| 07/03/2008 | WO2008077522A2 Use of polypeptides as coccidiostat and /or histomonastat |
| 07/03/2008 | WO2008077478A1 Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene |
| 07/03/2008 | WO2008077311A1 Hepatopoietin and use thereof |
| 07/03/2008 | WO2008077276A1 An injectable solution of spider venom and preparation thereof |
| 07/03/2008 | WO2008077241A1 Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections |
| 07/03/2008 | WO2008077236A1 Adp-ribosyl transferase fusion variant proteins |
| 07/03/2008 | WO2008077234A1 Synergistic effects of c3, cyclic amp and ciliary neurotrophic factor on neuronal survival and axonal regeneration |
| 07/03/2008 | WO2008077194A1 Receptor agonists |
| 07/03/2008 | WO2008057298A3 Lipidized interferon and uses thereof |
| 07/03/2008 | WO2008054540A9 Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| 07/03/2008 | WO2008053478A3 Compositions and methods for inhibiting hiv-1 replication and integrase activity |
| 07/03/2008 | WO2008049920A3 Il-21 variants |
| 07/03/2008 | WO2008048996A3 Sequential combination therapy |
| 07/03/2008 | WO2008027854A3 Pharmaceutical compositions comprising hgh for oral delivery |
| 07/03/2008 | WO2008027162A3 129xe biosensors and their use |
| 07/03/2008 | WO2008023077A3 Compositions and methods for modulating an immune response |
| 07/03/2008 | WO2008019289A3 Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| 07/03/2008 | WO2008002523A3 Matrix and method for isolation of hepatic progenitor cells |
| 07/03/2008 | WO2007149875A3 Compositions and methods for treating, preventing and/or reversing type-1 diabetes |
| 07/03/2008 | WO2007144882A3 Targeted chimeric proteins |
| 07/03/2008 | WO2007132269A3 Dub3 as a cancer therapy target |
| 07/03/2008 | WO2007119214A3 Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| 07/03/2008 | WO2007098122A3 Methods for the treatment of macular degeneration and related eye conditions |
| 07/03/2008 | WO2007095288A3 Methionine-containing protein or peptide compositions and methods of making and using |
| 07/03/2008 | WO2007092433A3 Osteoporosis associated markers and methods of use thereof |
| 07/03/2008 | WO2007070563A3 Stable solid forms of enterostatin |
| 07/03/2008 | WO2007070509A3 Epithelial sodium channel inhibiting agents and uses therefor |
| 07/03/2008 | WO2006134494A3 Anti-connexin compounds and therapeutic uses thereof |
| 07/03/2008 | WO2003068170A3 Enzyme treatment of foodstuffs for celiac sprue |
| 07/03/2008 | US20080161603 Amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium; side effect reduction; side effect reduction |
| 07/03/2008 | US20080161540 IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| 07/03/2008 | US20080161539 Recombinant colony stimulating factor, erythropoietin, interferon and/or growth hormone cell stimulating factor (G-CSF) for use in treatment and prevention of viral and cell proliferative disorders |
| 07/03/2008 | US20080161525 reaction product of polystyrene bound mesna (mercaptoethanesulfonic acid, sodium salt) and a sulfur-containing amino acid, preferably cysteine; chemical intermediates; anticarcinogenic agent; side effect reduction; heteroconjugate |
| 07/03/2008 | US20080161424 Compositions and Methods for the Systemic Treatment of Arthritis |
| 07/03/2008 | US20080161416 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| 07/03/2008 | US20080161415 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| 07/03/2008 | US20080161414 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| 07/03/2008 | US20080161262 Using oligonucleotide sequences specific to interleukin beta as blocking agents for treatment and prevention of juvenile idiopathic arthritis |
| 07/03/2008 | US20080161257 Oligonucleotide-Containing Pharmacological Compositions And Their Use |
| 07/03/2008 | US20080161255 Use of Parp Inhibitors for Prevention and Treatment of Diabetic and Insulin Resistance Complications |
| 07/03/2008 | US20080161250 Topical treatment or prevention of ocular infections |
| 07/03/2008 | US20080161246 Cytochrome P450 Oxidase Inhibitors and Uses Thereof |
| 07/03/2008 | US20080161245 Anthracycline-oligopeptide derivatives which have a protein-binding group such as maleimide and said oligopeptide is cleavable by the prostate-specific antigen (PSA); treating cancer |
| 07/03/2008 | US20080161244 Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes |
| 07/03/2008 | US20080161243 Chimeric B-type natriuretic peptide (BNP) polypeptide for use in treatment and prevention of cardiovascular disorders |
| 07/03/2008 | US20080161242 reduction of immunogenicity in protein therapeutics (biodrugs); for side effect reduction |
| 07/03/2008 | US20080161241 Preventing sustained monomorphic ventricular tachycardia following myocardial ischemia by administering etanercept; or bortezomib; inhibits substantial loss of beta-adrenergic receptor kinase (beta-ARK) activity |
| 07/03/2008 | US20080161240 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 07/03/2008 | US20080161239 Based on discovery that FBL2, a kind of F-box protein, which is a constituent of the SCF complex, binds to amyloid precursor protein (APP), and regulation of FBL2 expression influences the production of beta amyloid; SCF=(S-phase kinase-associated protein 1A (Skp1)-Cullin1-Ring box 1 (Rbx1) complex) |
| 07/03/2008 | US20080161238 Nucleic acid molecules encoding bacterial autoinducer inactivation proteins as targets for engineering disease resistance |
| 07/03/2008 | US20080161237 Formulation For a Viptadil |
| 07/03/2008 | US20080161236 Therapeutic nucleic acid-3'-conjugates |
| 07/03/2008 | US20080161235 Type 2 diabetes, metabolic syndrome, nonalcoholic fatty liver disease, polycystic ovarian syndrome and obesity; administering an antagonist to said receptor, for example an antibody, short interfering nucleic acid, or a modified sauvagin, corticotropin releasing factor (CRF), or a urocortin |
| 07/03/2008 | US20080161234 Treating bacterial vaginosis and fungal infections such as yeast infections; use of antibiotics may be reduced; lactoferrin enhances antimicrobial effect of lactate |
| 07/03/2008 | US20080161233 Sustained Release Formulation of a Peptide |
| 07/03/2008 | US20080161232 C5a Receptor Antagonist |
| 07/03/2008 | US20080161231 Methods and compositions for promoting organ development |
| 07/03/2008 | US20080161230 Methods and Kits for Stabilising, Protecting and Solubilising Proteins |
| 07/03/2008 | US20080161228 Using metabolomics to expedite drug discovery and development; invention provides means to select and advance most selective lead compounds from series of candidates based on metabolomic profiles which contain data regarding both expected or intended (e.g., on-target) and unexpected effects of compounds |
| 07/03/2008 | US20080161227 Peptide IPP is generated in high yields from preferably a small molecular weight protein having a high amount of -I-P-P- compared to -V-P-P- in its amino acid sequence; preferably the GMP fraction of kappa-casein is used; process comprises a single enzyme incubation step |
| 07/03/2008 | US20080161226 Activatable Clostridial Toxins |
| 07/03/2008 | US20080161225 Isolated and purified antifungal protein MAFP1 obtained from a Monascus species and purified polynucleotide comprising a nucleotide sequence encoding antifungal protein MAFP1; useful in treating and/or controlling fungal diseases, human pathogen such as P. variotii, and plant pathogen such as H. panici |
| 07/03/2008 | US20080160636 Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same |
| 07/03/2008 | US20080160617 Agent for inducing embryonic stem cell to ectodermal cell, method for obtaining the same, and use of the same |
| 07/03/2008 | US20080160613 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 07/03/2008 | US20080160594 Methods of Light Activated Release of Ligands from Endosomes |
| 07/03/2008 | US20080160576 Anti-alphabeta3 humanized monoclonal antibodies |
| 07/03/2008 | US20080160574 Chimeric coiled coil molecules |
| 07/03/2008 | US20080160541 Using transforming growth factor-beta -activated kinase-1 (TAK-1) and TAK1 binding protein 1(TAB-1) as evaluative tool in detection of modulators of interleukin and tumor necrosis factor activities |
| 07/03/2008 | US20080160535 Methods and Reagents for Detecting Target Binding by Nucleic Acid Ligands |
| 07/03/2008 | US20080160524 Using loop mediated isothermal amplification and invasive cleavage structure characterization as tools in identifying preferential nucleotide sequences |
| 07/03/2008 | US20080160121 Identifying an epileptogenic focus of a patient; and administering a botulinum toxin; direct infusion, circumventing the blood-brain barrier |
| 07/03/2008 | US20080160108 Method of treating muscular dystrophies with an inhibitor of histone deacetylase |
| 07/03/2008 | US20080160105 Administration of 2-methoxyestradiol or it derivatives such as colchicine or combretastatin A-4; for treating and/or preventing a pregnancy related disease; safer and more effective |
| 07/03/2008 | US20080160094 Comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein; brain disorders; kits; efficiently target and deliver substances |
| 07/03/2008 | US20080160092 Use of simple amino acids to form porous particles |
| 07/03/2008 | US20080160078 Nanoparticles for drug delivery |
| 07/03/2008 | US20080160077 bioactive lipophilic molecules, such as Coenzyme Q10 (CoQ10) and its reduced analogs (ubiquinols); increased bioavailability |
| 07/03/2008 | US20080160073 preparations of insulin and glucagon; for use when glucagon response to acute hypoglycemia is impaired or lost in patients with advanced Type 1 and Type 2 diabetes |
| 07/03/2008 | US20080160072 Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 07/03/2008 | US20080160071 Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 07/03/2008 | US20080160063 particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks |
| 07/03/2008 | US20080160061 stent having a protein patterning or bioactive patterning; contains a protein and an agent selected from an adhesion molecule including an RGD motif, a chemo-attractant of an endothelial cell, a NO releasing or generating material or agent, an agent that promotes endothelialization, or combinations |
| 07/03/2008 | US20080160060 administering locally a therapeutic amount of a Sost/Wise antagonist in conjunction with an osteoconductive biocompatible calcium salt scaffold; medical orthopedic or periodontal device; prevents kidney damage |
| 07/03/2008 | US20080160051 Hemostatic substance with a coating |
| 07/03/2008 | US20080160041 C-type lectin specific monoclonal antibody conjugate for use in reducing immune response to specific antigens; immunotherapy; immunosuppression; treating allergies and autoimmune diseases |